Taglich Brothers Weighs in on Cosmos Health FY2024 Earnings

Cosmos Health Inc. (NASDAQ:COSM) – Research analysts at Taglich Brothers dropped their FY2024 earnings per share estimates for shares of Cosmos Health in a research report issued on Monday, November 25th. Taglich Brothers analyst H. Halpern now anticipates that the company will post earnings per share of ($0.78) for the year, down from their prior estimate of ($0.48). The consensus estimate for Cosmos Health’s current full-year earnings is ($0.48) per share. Taglich Brothers also issued estimates for Cosmos Health’s Q4 2024 earnings at ($0.09) EPS, Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at $0.01 EPS and FY2025 earnings at $0.01 EPS.

Cosmos Health Stock Performance

Shares of Cosmos Health stock opened at $0.81 on Thursday. The business’s 50 day moving average price is $0.78 and its 200 day moving average price is $0.91. The company has a market cap of $18.91 million, a price-to-earnings ratio of -0.33 and a beta of 5.72. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.24 and a current ratio of 1.44. Cosmos Health has a one year low of $0.47 and a one year high of $1.65.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names.